Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Acute Inflammation III: Local and Systemic Effects01:25

Acute Inflammation III: Local and Systemic Effects

Acute inflammation produces a coordinated set of local and systemic changes that limit injury, eliminate pathogens, and initiate repair. These responses arise within minutes of infection, trauma, or chemical insult and are driven by vascular alterations and leukocyte-derived mediators. When the stimulus resolves, the reaction typically abates within days.Local EffectsAt the site of injury, arteriolar vasodilation increases blood flow, resulting in redness and warmth. Simultaneously, increased...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Skin Diseases and Disorders01:23

Skin Diseases and Disorders

Skin is the first line of defense and encounters a variety of microbes. Some pathogenic strains are often the cause of a broad range of infections of the skin and other body systems. These conditions can affect people of all ages and may have different causes, including genetic factors, infections, autoimmune reactions, environmental factors, and lifestyle choices.
Gram-positive Staphylococcus spp. and Streptococcus spp. are responsible for many of the most common skin infections. However, many...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cardiovascular Comorbidities and Risk in Hidradenitis Suppurativa: A Systematic Review and Meta-analysis.

The British journal of dermatology·2026
Same author

Correction to: Past, Present, and Future of Sodium Hypochlorite in Dermatology: A Scoping Review.

American journal of clinical dermatology·2026
Same author

Clinical Severity and Outcome Measures in Seborrheic Dermatitis: A Systematic Review.

Dermatology and therapy·2026
Same author

Efficacy of abrocitinib and dupilumab in itch-dominant atopic dermatitis: An analysis of 2 trials.

Journal of the European Academy of Dermatology and Venereology : JEADV·2026
Same author

Prevalence of atopic comorbidities in prurigo nodularis: A systematic review and meta-analysis.

Journal of the European Academy of Dermatology and Venereology : JEADV·2026
Same author

Expert Recommendations for the Diagnosis and Management of Chronic Hand Eczema in the United States.

American journal of clinical dermatology·2026

Related Experiment Video

Updated: May 19, 2026

Clinical Application of Intense Pulsed Light Therapy and Radio Frequency for Treatment of Ocular Surface Diseases
07:36

Clinical Application of Intense Pulsed Light Therapy and Radio Frequency for Treatment of Ocular Surface Diseases

Published on: July 3, 2025

PDE4 Inhibition in Dermatologic Disease: Impacts Beyond Inflammation.

Keana Khodadad1, Nicole E Chin2, Raj Chovatiya1,3

  • 1Rosalind Franklin University of Medicine and Science Chicago Medical School, North Chicago, Illinois, USA.

International Journal of Dermatology
|May 18, 2026
PubMed
Summary

Phosphodiesterase 4 (PDE4) inhibitors offer anti-inflammatory benefits in skin diseases. Beyond inflammation, PDE4 inhibition impacts skin pigmentation, barrier function, nerve signaling, and wound healing, expanding their therapeutic potential.

Keywords:
fibrosisinflammationphosphodiesterase 4 (PDE4)pigmentationpruritus

More Related Videos

The Efficacy and Underlying Pathway Mechanisms of ShiDuGao Treatment for Anus Eczema Based on GEO Datasets and Network Pharmacology
12:34

The Efficacy and Underlying Pathway Mechanisms of ShiDuGao Treatment for Anus Eczema Based on GEO Datasets and Network Pharmacology

Published on: January 12, 2024

Related Experiment Videos

Last Updated: May 19, 2026

Clinical Application of Intense Pulsed Light Therapy and Radio Frequency for Treatment of Ocular Surface Diseases
07:36

Clinical Application of Intense Pulsed Light Therapy and Radio Frequency for Treatment of Ocular Surface Diseases

Published on: July 3, 2025

The Efficacy and Underlying Pathway Mechanisms of ShiDuGao Treatment for Anus Eczema Based on GEO Datasets and Network Pharmacology
12:34

The Efficacy and Underlying Pathway Mechanisms of ShiDuGao Treatment for Anus Eczema Based on GEO Datasets and Network Pharmacology

Published on: January 12, 2024

Area of Science:

  • Dermatology
  • Pharmacology
  • Molecular Biology

Background:

  • Phosphodiesterase 4 (PDE4) enzymes regulate cyclic adenosine monophosphate (cAMP) signaling, influencing cellular responses.
  • PDE4 inhibitors are established anti-inflammatory treatments for dermatologic conditions.
  • Emerging evidence indicates broader roles for PDE4 inhibition in skin physiology.

Purpose of the Study:

  • To review mechanistic, preclinical, and clinical evidence on the multifaceted roles of PDE4 inhibition in skin.
  • To synthesize current understanding of PDE4 inhibitor effects beyond inflammation.

Main Methods:

  • Comprehensive literature review of PubMed/MEDLINE, Embase, and ClinicalTrials.gov.
  • Searches included terms like "PDE4," "phosphodiesterase 4," and specific drug names (apremilast, crisaborole, roflumilast, orismilast).
  • Inclusion of preclinical studies, clinical trials, and mechanistic investigations.

Main Results:

  • PDE4 inhibition prevents cAMP degradation, activating protein kinase A (PKA) signaling.
  • Effects include anti-inflammatory actions, influence on melanocyte signaling and pigmentation, enhanced epidermal barrier proteins, modulated sensory neuron activity, and promotion of wound healing.
  • These effects are supported by mechanistic and clinical data across various dermatologic conditions.

Conclusions:

  • PDE4 inhibitors possess pleiotropic effects in the skin, regulating pigmentation, barrier integrity, neural signaling, and tissue repair.
  • Their ability to integrate immunologic and non-immunologic pathways highlights their role in cutaneous homeostasis.
  • Further research is needed to address study design heterogeneity and limited long-term data for broader generalizability.